Connect with us

Science

Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE, AZN, MRNA, MRK, JNJ, BNTX)

Just when we started to think it was over, Omicron popped up and reminded us that this thing is a whole lot more complex than just a simple bug. The pandemic has been with us for two years now, and it looks more and more like it will be with us for a…

Published

on

Just when we started to think it was over, Omicron popped up and reminded us that this thing is a whole lot more complex than just a simple bug. The pandemic has been with us for two years now, and it looks more and more like it will be with us for a whole lot longer.

The latest idea is that Omicron could be the last wave of what scientists frame as a “pandemic”. But the next stage is the “endemic” – the longstanding participation of Covid-19 in the global human microbiome. In other words, we are going to need to shift to long-term solutions to restore our way of life.

For investors, this defines the parameters of a long-term investment theme worth paying attention to. With that in mind, we take a look at a few of the most interesting opportunities in the space below.

 

Novavax Inc. (Nasdaq:NVAX) focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases.

It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.

Novavax Inc. (Nasdaq:NVAX) recently announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval for provisional registration of NVX-CoV2373, Novavax’ COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine will be supplied to Australia under the brand name Nuvaxovid.

“The grant of provisional registration of Nuvaxovid by the TGA reflects Novavax’ increasing momentum around the globe and represents the first-protein based COVID-19 vaccine authorized for use in Australia,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “While the world continues to grapple with the ever-changing nature of the virus, we look forward to delivering our vaccine to the people of Australia. We would also like to extend our gratitude to the Australian clinical trial participants who contributed so significantly to the development of our vaccine.”

The stock has suffered a bit of late, with shares of NVAX taking a hit in recent action, down about -31% over the past week. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -53%.

Novavax Inc. (Nasdaq:NVAX) managed to rope in revenues totaling $178.8M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 13.9%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($1.9B against $1.8B).

 

Oncotelic Therapeutics Inc (OTC US:OTLC) bills itself as an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma.

OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19, with data cleaning and evaluation and datalock ongoing.

Oncotelic Therapeutics Inc (OTC US:OTLC) most recently announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients. Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome.

“It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.”

OTLC shares are up over 60% since November, leading the Covid stock space.

Oncotelic Therapeutics Inc (OTC US:OTLC) noted in its release that it has identified 30 high entropy amino acid residues which underwent a progressive evolution to arrive at the current dominant variant – Delta variant. The virus underwent mutational waves, with the first wave made up of structural proteins important in its infectivity, and the second wave made up of the ORFs important for its contagion. The most important driver of the second wave is ORF8 mutations at residue 119 and 120. Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone. More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.

 

Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Pfizer Inc. (NYSE:PFE) recently announced that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

“The reality for patients living with chronic inflammatory skin disease such as moderate-to-severe atopic dermatitis is that many experience debilitating symptoms that are not managed by current treatment options. Today’s approval of CIBINQO will provide an important new oral option that could help those who have yet to find relief,” said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. “In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population.”

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action PFE shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -5% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -8%.

Pfizer Inc. (NYSE:PFE) managed to rope in revenues totaling $24.1B in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 98.6%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($29.7B against $41.8B, respectively).

Other key tickers tied to the Covid theme include AstraZeneca PLC ADR (Nasdaq:AZN), Moderna Inc. (Nasdaq:MRNA), Merck & Co. Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), and BioNTech SE ADR (Nasdaq:BNTX).

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

The post Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE, AZN, MRNA, MRK, JNJ, BNTX) appeared first on Wall Street PR.

Read More

Continue Reading

Government

Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change

The outlook for Revive Therapeutics Ltd. (CNSX: RVV, OTCMKTS: RVVTF) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat…

Published

on

The outlook for Revive Therapeutics Ltd. (CNSX: RVV, OTCMKTS: RVVTF) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19 got a little brighter on Thursday. The U.S Food and Drug Administration appears to be amenable to the company’s submitted request to change the trial’s primary endpoints to a ‘symptoms’ focus, as announced on May 16. Although the FDA did not officially grant primary endpoint change yet, Thursday’s news was enough to catalyze forward-looking investors into action, sending Revive shares higher in the U.S. by +21.06% on the best volume in six weeks.

Revive Therapeutics reported that pursuant to its submitted request to change the trial’s primary endpoints to a ‘symptoms’ focus, it has received “positive comments” from the FDA in regards to its request to amend new primary efficacy endpoints for the current trial. This includes the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in clinical outcome. The positive comments following Revive’s May 16 submission are a constructive sign that the FDA is an ally in the endpoint change process.

Furthermore—and perhaps unexpectedly—the FDA agreed that Revive Therapeutics may unblind the pre-dose-selection data for the first 210 patients of the study to further support the new primary endpoint. In essence, the FDA is giving Revive an opportunity to look directly at a portion of the data to make sure they want to proceed with the proposed endpoint change. Up to this point, the entire dataset of the 715 patients already tabulated in the trial have been blinded to the company.

Revive will submit a Data Access Plan to the FDA in early June 2022 with the aim to unblind the pre-dose selection data and submit the amended study protocol with the new primary efficacy endpoints to the FDA.

Under FDA Guidance for Clinical Trial Sponsors, knowledge of unblinded interim comparisons from a clinical trial is generally not necessary for those conducting or sponsoring it. Further, such knowledge can bias the outcome of the study by inappropriately influencing its continuing conduct or the plan of analyses. Unblinded interim data and results of comparative interim analyses, therefore, should generally not be accessible by anyone other than Data Monitoring Committee (DMC)—aka Data Safety Monitoring Board (DSMB) in the current trial—or the statisticians performing these analyses and presenting them to the DMC.

So for Revive Therapeutics to be allowed to peek under the hood before proceeding with symptoms endpoint change may be inferred as a goodwill gesture by the FDA.

Furthermore, Revive Therapeutics confirmed that the DSMB is scheduled to meet thereafter to evaluate the interim clinical and safety data and may make a recommendation on the study. This could involve the recommendation to continue or halt the study due to positive efficacy based on the resolution of symptoms of COVID-19—assuming the primary endpoint change to symptoms is approved. The DSMB could also recommend that the FDA consider Bucillamine for potential Emergency Use Authorization for the treatment of COVID-19 symptoms, should the data support such a recommendation.

The DSMB has previously met on three separate occasions and supported the continuation of the study each time. To date, no serious adverse events or safety concerns have been reported.

TDR will have additional coverage as events warrant.

The post Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change appeared first on The Dales Report.

Read More

Continue Reading

Government

Sheila Ochugboju named Executive Director of Alliance for Science

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications…

Published

on

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications initiative dedicated to promoting access to scientific innovation as a means of enhancing food security, improving environmental sustainability, and raising the quality of life globally. Her start date is June 1.

Credit: Image provided/Sheila Ochugboju

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications initiative dedicated to promoting access to scientific innovation as a means of enhancing food security, improving environmental sustainability, and raising the quality of life globally. Her start date is June 1.

“We are delighted that Dr. Ochugboju will soon be joining us,” said BTI President David Stern. “The Alliance plays a vital role in connecting a range of stakeholders with up-to-date and vital information about how scientific advances can contribute to the future of the planet’s health, an effort that aligns perfectly with BTI’s mission to advance and communicate scientific discovery in plant biology to improve agriculture, protect the environment, and enhance human health.”

“We are fortunate to have someone with Sheila’s experience, connections and vision in this role,” Stern added.

Ochugboju is a leader in science communication and has been a global advocate for science technology and innovation for more than 20 years. She was most recently the Head of Strategic Communications at the Africa Centres for Disease Control and Prevention (Africa CDC), supporting vaccine delivery communication across Africa and advocating for vaccine equity.

She is also a founding member of the Network of African Women Environmentalists (NAWE), leading in the development of flagship initiatives and products such as the Earth Science Cafes, The Youth Earth Guardians and Landscape Mentors network and the Earth Reflections Podcast, which was rated amongst the leading environment podcasts in Africa in 2020.

“I am excited to join the Boyce Thompson Institute, because together with the Alliance for Science we can offer new lenses, tools, and partnerships to transform how the world understands the role of science in addressing global challenges,” said Ochugboju. “The COVID-19 pandemic, climate change and now food security challenges are teaching everyone that good science communication can literally save lives and livelihoods.”

Founded in 2014, AfS is a global communications initiative that seeks to counter misinformation about agricultural biotechnology, climate change, nuclear power, vaccines, COVID-19 and other contemporary science issues.

To support its work, the Alliance relies on a global network of about 14,000 science allies who engage in their local communities to advance science-based policies. AfS has trained more than 900 science champions, including scientists, farmers, journalists, healthcare professionals and students, in 48 countries to communicate effectively about biotechnology.

“After a comprehensive executive search, we are thrilled to have found someone like Dr. Ochugboju, who has the knowledge and ability to broaden the horizon of the Alliance for Science and bring resources to counter misinformation across a more substantial expanse of scientific endeavor, especially including climate change,” said Ronnie Coffman, Professor of Global Development at Cornell University and Interim Director of AfS.  

Ochugboju graduated with a degree in Medical Biochemistry and then received her Ph.D. in Plant Biochemistry from Royal Holloway, University of London in 1996. She was awarded the Daphne Jackson Trust Post-Doctoral Research Fellowship, based at the Centre for Ecology & Hydrology, St. Hilda’s College, University of Oxford in 1998.

She has lived and worked in Africa, Europe and the Middle East. In 2016, she received a WINGS WorldQuest Women of Discovery Award for developing and leading pioneering African science, technology and innovation projects. Ochugboju was also appointed as a Global Roving Ambassador for the county government of Kisumu, Kenya, in charge of the portfolio for Transformative Science and Urban Resilience.

About Boyce Thompson Institute:

Opened in 1924, Boyce Thompson Institute is a premier life sciences research institution located in Ithaca, New York. BTI scientists conduct investigations into fundamental plant and life sciences research with the goals of increasing food security, improving environmental sustainability in agriculture, and making basic discoveries that will enhance human health. Throughout this work, BTI is committed to inspiring and educating students and to providing advanced training for the next generation of scientists. BTI is an independent nonprofit research institute that is also affiliated with Cornell University. For more information, please visit BTIscience.org.

 

###


Read More

Continue Reading

Spread & Containment

Lab, crab and robotic rehab

I was in Berkeley a couple of months back, helping TechCrunch get its proverbial ducks in a row before our first big climate event (coming in a few weeks,…

Published

on

I got previews of a number of projects I hope to share with you in the newsletter soon, but one that really caught my eye was FogROS, which was just announced as part of the latest ROS (robot operating system) rollout. Beyond a punny name that is simultaneously a reference to the cloud element (fog/cloud — not to mention the fact that the new department has killer views of San Francisco and frequent visitor, Karl) and problematic French cuisine, there’s some really compelling potential here.

I’ve been thinking about the potential impact of cloud-based processing quite a bit the last several years, independent of my writing about robots. Specifically, a number of companies (Microsoft, Amazon, Google) have been betting big on cloud gaming. What do you do when you’ve seemingly pushed a piece of hardware to its limit? If you’ve got low enough latency, you can harness remote servers to do the heavy lifting. It’s something that’s been tried for at least a decade, to varying effect.

Image Credits: ROS

Latency is, of course, a major factor in gaming, where being off by a millisecond can dramatically impact the experience. I’m not fully convinced that experience is where it ought to be quite yet, but it does seem the tech has graduated to a point where off-board processing makes practical sense for robotics. You can currently play a console game on a smartphone with one of those services, so surely we can produce smaller, lighter-weight and lower-cost robots that rely on a remote server to complete resource-intensive tasks like SLAM processing.

The initial application will focus on AWS, with plans to reach additional services like Google Cloud and Microsoft Azure. Watch this space. There are many reasons to be excited. Honestly, there’s a lot to be excited about in robotics generally right now. This was one of the more fun weeks in recent memory.

V Bionic's exoskeleton glove shown without its covering.

Image Credits: V Bionic

Let’s start with the ExoHeal robotic rehabilitation gloves. The device, created by Saudi Arabian V Bionic, nabbed this year’s Microsoft Imagine Cup. The early-stage team is part of a proud tradition of healthcare exoskeletons. In this case, it’s an attempt to rehab the hand following muscle and tendon injuries. Team leader Zain Samdani told TechCrunch:

Flexor linkage-driven movement gives us the flexibility to individually actuate different parts of each finger (phalanges) whilst keeping the device portable. We’re currently developing our production-ready prototype that utilizes a modular design to fit the hand sizes of different patients.

Image Credits: Walmart

This is the third week in a row Walmart gets a mention here. First it was funding for GreyOrange, which it partnered with in Canada. Last week we noted a big expansion of the retail giant’s deal with warehouse automation firm, Symbotic. Now it’s another big expansion of an existing deal — this time dealing with the company’s delivery ambitions.

Like Walmart’s work with robotics, drone delivery success has been…spotty, at best. Still, it’s apparently ready to put its money where its mouth is on this one, with a deal that brings DroneUp delivery to 34 sites across six U.S. states. Quoting myself here:

The retailer announced an investment in the 6-year-old startup late last year, following trial deliveries of COVID-19 testing kits. Early trials were conducted in Bentonville, Arkansas. This year, Arizona, Florida, Texas and DroneUp’s native Virginia are being added to the list. Once online, customers will be able to choose from tens of thousands of products, from Tylenol to hot dog buns, between the hours of 8 a.m. and 8 p.m.

Freigegeben für die Berichterstattung über das Unternehemn Wingcopter bis zum 25.01.2026. Mit Bitte um Urhebervermerk v.l.: Jonathan Hesselbarth, Tom Plümmer und Ansgar Kadura von Wingcopter GmbH. Image Credits: © Jonas Wresch / KfW

There are still more question marks around this stuff than anything, and I’ve long contended that drone delivery makes the most sense in remote and otherwise hard to reach areas. That’s why something like this Wingcopter deal is interesting. Over the next five years, the company plans to bring 12,000 of its fixed-wing UAVs to 49 countries across Sub-Saharan Africa. It will cover spots that have traditionally struggled with infrastructural issues that have made it difficult to deliver food and medical supplies through more traditional means.

“With the looming food crisis on the African continent triggered by the war in Ukraine, we see great potential and strong social impact that drone-delivery networks can bring to people in all the countries in Sub-Saharan Africa by getting food to where it is needed most,” CEO Tom Plümmer told TechCrunch. “Especially in remote areas with weak infrastructure and those areas that are additionally affected by droughts and other plagues, Wingcopter’s delivery drones will build an air bridge and provide food from the sky on a winch to exactly where it is needed.”

Legitimately exciting stuff, that.

Image Credits: Dyson

In more cautiously optimistic news, Dyson dropped some interesting news this week, announcing that it has been (and will continue) pumping a lot of money into robotic research. Part of the rollout includes refitting an aircraft hangar at Hullavington Airfield, a former RAF station in Chippenham, Wiltshire, England that the company purchased back in 2016.

Some numbers from the company:

Dyson is halfway through the largest engineering recruitment drive in its history. Two thousand people have joined the tech company this year, of which 50% are engineers, scientists, and coders. Dyson is supercharging its robotics ambitions, recruiting 250 robotics engineers across disciplines including computer vision, machine learning, sensors and mechatronics, and expects to hire 700 more in the robotics field over the next five years. The master plan: to create the UK’s largest, most advanced, robotics center at Hullavington Airfield and to bring the technology into our homes by the end of the decade.

The primary project highlighted is a robot arm with a number of attachments, including a vacuum and a human-like robot hand, which are designed to perform various household tasks. Dyson has some experience building robots, primarily through its vacuums, which rely on things like computer vision to autonomously navigate. Still, I say “cautiously optimistic,” because I’ve seen plenty of non-robotics companies showcase the technology as more of a vanity project. But I’m more than happy to have Dyson change my mind.

Image Credits: Hyundai

Hyundai, of course, has been quite aggressive in its own robotics dreams, including its 2020 acquisition of Boston Dynamics. The carmaker this week announced that part of its massive new $10 billion investment plans will include robotics, with a focus of actually bringing some of its far-out concepts to market.

Another week, another big round for logistics/fulfillment robotics, as Polish firm Nomagic raised $22 million to expand its offerings. The company’s primary offering is a pick and place arm that can move and sort small goods. Khosla Ventures and Almaz Capital led the round, which also featured European Investment Bank, Hoxton Ventures, Capnamic Ventures, DN Capital and Manta Ray.

Amazon Astro with periscope camera

The periscope camera pops out and extends telescopically, enabling Astro to look over obstacles and on counter tops. A very elegant design choice. Image Credits: Haje Kamps for TechCrunch

We finally got around to reviewing Amazon’s limited-edition home robot, Astro, and Haje’s feelings were…mixed:

It’s been fun to have Astro wandering about my apartment for a few days, and most of the time I seemed to use it as a roving boom box that also has Alexa capabilities. That’s cute, and all, but $1,000 would buy Alexa devices for every thinkable surface in my room and leave me with enough cash left over to cover the house in cameras. I simply continue to struggle with why Astro makes sense. But then, that’s true for any product that is trying to carve out a brand new product category.

A tiny robot crab scuttles across the frame. Image Credits: Northwestern University

And finally, a tiny robot crab from Northwestern University. The little guy can be controlled remotely using lasers and is small enough to sit on the side of a penny. “Our technology enables a variety of controlled motion modalities and can walk with an average speed of half its body length per second,” says lead researcher, Yonggang Huang. “This is very challenging to achieve at such small scales for terrestrial robots.”

Image Credits: Bryce Durbin/TechCrunch

Scuttle, don’t walk to subscribe to Actuator.

Read More

Continue Reading

Trending